Setmelanotide

CHEMBL3301624 Phase 4 Disetujui Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1117.3 g/mol

LogP

-2.5

Phase

4

Setmelanotide is a melanocortin-4 receptor (MC4R) agonist peptide used for chronic weight management in patients with obesity due to specific genetic deficiencies affecting the leptin-melanocortin pathway, including POMC, PCSK1, or LEPR deficiency. By activating MC4R in the hypothalamus, it restores impaired satiety signaling in patients with these rare monogenic obesity disorders, reducing appetite and promoting weight loss. It is the first approved therapy specifically targeting genetically defined melanocortin pathway deficiencies.

Berat Molekul

1117,3000 g/mol

LogP

-2,50

TPSA

500,00 Å²

Lipinski RO5

Gagal

Area Terapeutik

Obesity

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Struktur 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@@H](C)NC1=O

InChI

InChI=1S/C49H68N18O9S2/c1-26-41(70)63-37(20-30-22-55-25-59-30)46(75)64-35(18-28-10-4-3-5-11-28)44(73)62-34(15-9-17-57-49(53)54)43(72)65-36(19-29-21-58-32-13-7-6-12-31(29)32)45(74)66-38(40(50)69)23-77-78-24-39(47(76)60-26)67-42(71)33(61-27(2)68)14-8-16-56-48(51)52/h3-7,10-13,21-22,25-26,33-39,58H,8-9,14-20,23-24H2,1-2H3,(H2,50,69)(H,55,59)(H,60,76)(H,61,68)(H,62,73)(H,63,70)(H,64,75)(H,65,72)(H,66,74)(H,67,71)(H4,51,52,56)(H4,53,54,57)/t26-,33+,34+,35-,36+,37+,38+,39+/m1/s1

Molecular Formula

C49H68N18O9S2

HBD / HBA

15 / 14

Ikatan yang Dapat Dirotasi

18

Atom Berat

78

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

Setmelanotide is a melanocortin-4 receptor (MC4R) agonist peptide used for chronic weight management in patients with obesity due to specific genetic deficiencies affecting the leptin-melanocortin pathway, including POMC, PCSK1, or LEPR deficiency. By activating MC4R in the hypothalamus, it restores impaired satiety signaling in patients with these rare monogenic obesity disorders, reducing appetite and promoting weight loss. It is the first approved therapy specifically targeting genetically defined melanocortin pathway deficiencies.

Yes, Setmelanotide is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3301624. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 11993702. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Mencari informasi yang ramah bagi pasien?

Setmelanotide di PillFYI

Struktur

Data Cepat

Rumus: C49H68N18O9S2
Sinonim: 1

Tautan Eksternal

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.